Latest News Johnson & Johnson deserves more credit for another healthy quarter and strong guidance Published 6 days ago on January 25, 2023 By Lyron Foster The new year has been tough on pharmaceutical stocks, including JNJ. But it should not be read as an indictment on the company’s operations. Related Topics: Up Next Microsoft shares are ‘just north’ of expensive after earnings, Tim Seymour says Don't Miss BlockFi secret financials show a $1.2 billion relationship with Sam Bankman-Fried’s crypto empire Lyron Foster Lyron Foster is a Hawaii based African American Musician, Author, Actor, Blogger, Filmmaker, Philanthropist and Multinational Serial Tech Entrepreneur. Continue Reading You may like Comments
